TRIUMEQ效果怎样呢？

Suimeike () is a new drug used to treat AIDS without considering food effects. For adults and adolescents weighing 40kg or more, the recommended dose of TRIUMEQ is one tablet, once daily. Because Trimax is a fixed-dose tablet and the dose cannot be reduced, adults or adolescents who weigh less than 40 kg should not give Trimax. Before taking Suimeikai, you need to complete the test to determine whether you carry the special type of "HLA-B*5701" gene.

TRIUMEQ is a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir) 600 mg and lamivudine 300 mg. It is suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a weight of at least 40 kg).

TRIUMEQ has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the life spans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day or one tablet at a time on the Chinese market. The approval of TRIUMEQ fills this gap and meets the urgent need for convenient medication use by doctors and patients."

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). Existing research shows that one year (48 weeks) after HIV infection treatment, 93% of HIV-infected patients turned negative.